KRYS
Krystal Biotech, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website krystalbio.com
- Employees(FY) 210
- ISIN US5011471027
Performance
-4.87%
1W
-0.61%
1M
-10.36%
3M
+8.53%
6M
+43.56%
YTD
+69.98%
1Y
Profile
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Technical Analysis of KRYS 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-12 19:00
KRYS: Raising target price to $197.00(Argus Research)
- 2024-11-12 13:02
High Growth Tech Stocks Featuring Three Prominent US Companies(Simply Wall St.)
- 2024-11-12 07:00
- 2024-11-11 18:00
- 2024-11-11 06:06
US Exchange Highlights 3 Growth Stocks With Strong Insider Ownership(Simply Wall St.)
- 2024-11-07 08:04
- 2024-11-06 07:00
- 2024-11-05 19:00
KRYS: Lowering target price to $183.00(Argus Research)
- 2024-11-05 18:00
- 2024-11-05 13:58
- 2024-11-05 05:48
Krystal Biotech Third Quarter 2024 Earnings: EPS Beats Expectations(Simply Wall St.)
- 2024-11-05 02:52
Q3 2024 Krystal Biotech Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-05 02:04
- 2024-11-04 09:10
- 2024-11-04 08:34
Krystal Biotech's Q3 Net Income Falls, Revenue Rises(MT Newswires)
- 2024-11-04 08:00
- 2024-11-03 19:00
- 2024-11-01 08:30
- 2024-10-31 21:02
- 2024-10-29 10:01
- 2024-10-28 10:01
- 2024-10-28 07:00
- 2024-10-27 19:00
- 2024-10-18 12:00
- 2024-10-16 15:02
- 2024-10-14 10:02
Exploring Three High Growth Tech Stocks in the United States(Simply Wall St.)
- 2024-10-11 15:31
US Growth Stocks With High Insider Ownership(Simply Wall St.)
- 2024-10-08 20:00
KRYS: Lowering target price to $184.00(Argus Research)
- 2024-09-27 13:40
- 2024-09-26 11:40
Page 1 of 9
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.